Virpax Pharmaceuticals SaidOn March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
Virpax Pharmicals表示,3月15日收到纳斯达克的来信,称该公司已恢复遵守上市规则5550(A)(2)
Virpax Pharmaceuticals SaidOn March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
Virpax Pharmicals表示,3月15日收到纳斯达克的来信,称该公司已恢复遵守上市规则5550(A)(2)
使用浏览器的分享功能,分享给你的好友吧